Organization
Evangelische Huyssens-Stiftung/Knappschaft GmbH
4 abstracts
Abstract
Effect of chemotherapy/targeted therapy alone vs. chemotherapy/targeted therapy followed by radical surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction: The IKF-575/RENAISSANCE phase III trial.Org: Krankenhaus Nordwest, University Cancer Center Frankfurt and Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Frankfurter Institut für Klinische Krebsforschung IKF am Krankenhaus Nordwest, Third Department of Internal Medicine, Klinikum Rechts der Isar,
Abstract
68Ga-FAPI-46 PET for cancer imaging: A prospective single-arm clinical trial.Org: University of Duisburg-Essen, German Cancer Consortium (DKTK), Partner Site Munich, University Hospital Essen, West German Cancer Center, University Hospital Essen, Kliniken Essen-Mitte,
Abstract
UP-NEXT (GOG-3049/ENGOT-Ov71-NSGO-CTU): A study of upitifamab rilsodotin (UpRi), a NaPi2b-directed antibody drug conjugate (ADC), in platinum-sensitive recurrent ovarian cancer.Org: Stephenson Cancer Center/University of Oklahoma Health Sciences Center and Sarah Cannon Research Institute, Sarah Cannon Research Institute/Tennessee Oncology, Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung/Knappschaft GmbH, The Ohio State University - James Cancer Hospital,
Abstract
Uterine sarcoma patients who underwent morcellation: Who are they? Results of the prospective intergroup real-world registry for gynecological sarcoma in Germany (REGSA- NOGGO RU1).Org: Charité - Universitätsmedizin Berlin, Berlin, Germany, Helios Klinikum Berlin-Buch, Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung/Knappschaft GmbH, Tuebingen University Hospital,